Non-coding RNAs in drug resistance of head and neck cancers: A review

Fengsheng Dai, Li Dai, Xiwang Zheng, Yujia Guo, Yuliang Zhang, Min Niu, Yan Lu, Huizheng Li, Rui Hou, Yu Zhang, Shuxin Wen, Wanglai Hu, Changming An, Yongyan Wu, Wei Gao

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)


Head and neck cancer (HNC), which includes epithelial malignancies of the upper aerodigestive tract (oral cavity, oropharynx, pharynx, hypopharynx, larynx, and thyroid), are slowly but consistently increasing, while the overall survival rate remains unsatisfactory. Because of the multifunctional anatomical intricacies of the head and neck, disease progression and therapy-related side effects often severely affect the patient's appearance and self-image, as well as their ability to breathe, speak, and swallow. Patients with HNC require a multidisciplinary approach involving surgery, radiation therapy, and chemotherapeutics. Chemotherapy is an important part of the comprehensive treatment of tumors, especially advanced HNC, but drug resistance is the main cause of poor clinical efficacy. The most important determinant of this phenomenon is still largely unknown. Recent studies have shown that non-coding RNAs have a crucial role in HNC drug resistance. In addition, they can serve as biomarkers in the diagnosis, treatment, and prognosis of HNCs. In this review, we summarize the relationship between non-coding RNAs and drug resistance of HNC, and discuss their potential clinical application in overcoming HNC chemoresistance.

Original languageEnglish
Article number110231
JournalBiomedicine and Pharmacotherapy
Publication statusPublished - Jul 2020


Dive into the research topics of 'Non-coding RNAs in drug resistance of head and neck cancers: A review'. Together they form a unique fingerprint.

Cite this